Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Roche aims for MacroGenics bullseye with $370M DART deal .After its $1.7 billion deal to buy out cancer biotech Ignyta in the dying days of 2017 Roche, ahead … Continue reading
Cet article #news #biotech Roche aims for MacroGenics bullseye with $370M DART deal est apparu en premier sur Biotech 365.
Original Article: #news #biotech Roche aims for MacroGenics bullseye with $370M DART deal
NEXT ARTICLE